Serotonin warning for users of SSRIs

Share this article:
The FDA says development of a potentially life-threatening serotonin syndrome may occur in treatment with four selective serotonin reuptake inhibitors: Lilly's Cymbalta (duloxetine HCl) delayed release capsules, Wyeth's Effexor (venlafaxine HCL) tablets and Effexor extended release capsules, Lilly's Prozac (fluoxetine capsules and oral solution) and Lilly's Symbyax (olanzapine and fluoxetine HCL capsules).

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Legal/Regulatory


Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.